Surrey, United Kingdom

Nigel Richard Whittle

This inventor holds 2 USPTO granted patents. Top assignees: Celltech Limited, Celltech Therapeutics Limited. Active years: 1993-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nigel Richard Whittle. Retrieved from https://idiyas.com/inventor/nigel-richard-whittle-azedazbl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 470(Granted Patents)


Company Filing History:


Years Active: 1993-1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Nigel Richard Whittle

Introduction

Nigel Richard Whittle is a notable inventor based in Surrey, GB. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant antibodies. With a total of 2 patents to his name, Whittle's work has had a considerable impact on medical research and therapeutic applications.

Latest Patents

Whittle's latest patents include a groundbreaking invention related to recombinant antibodies. The first patent provides an altered antibody molecule (AAM) featuring a hinge region with a different number of cysteine residues compared to the traditional hinge region associated with the CH1 domain of antibody molecules. This innovation is produced using recombinant DNA technology. The second patent focuses on recombinant antibodies and methods for their production, emphasizing the importance of surface characteristics in these molecules.

Career Highlights

Throughout his career, Nigel Whittle has worked with prominent companies in the biotechnology sector, including Celltech Therapeutics Limited and Celltech Limited. His experience in these organizations has allowed him to refine his expertise and contribute to significant advancements in antibody technology.

Collaborations

Whittle has collaborated with esteemed colleagues such as Mark William Bodmer and John Robert Adair. These partnerships have fostered a collaborative environment that has led to innovative solutions in the field of biotechnology.

Conclusion

Nigel Richard Whittle's contributions to the field of recombinant antibodies demonstrate his commitment to advancing medical science. His patents and collaborations reflect a dedication to innovation that continues to influence the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…